J&J beats earnings estimates, eyes mid-2027 hip and knee unit spinoff

4

By Michael Erman and Sriparna Roy Oct 13 (Reuters) – Johnson & Johnson reported a slightly higher-than-expected profit on Tuesday driven by strong sales of immune disease treatment Tremfya, and said

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)